All In Biotech

Drug Trial Radar · NCT06379971

Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development

Clinical Trial of Maternal Choline Supplements to Mitigate Effects of Prenatal Cannabis Exposure on Early Brain Development

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Nov 25, 2024

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
University of Colorado, DenverAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women who have used cannabis products during the current pregnancy improves the offspring\'s brain-related development during the first 3 months. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcomes are the child\'s brain responses to sound at 4 weeks corrected age and infant behaviors at 3 months corrected age as reported by the primary caregiver. Secondary outcomes include motor, socio-emotional, language and cognitive development.

Conditions

  • Child Development
  • Cannabis Use

Interventions

  • PlaceboDrug

    Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.

  • CholineDrug

    Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infant Behavior Questionnaire-Revised (IBQ-R) Orienting/Regulation IndexTime frame: 3 months corrected age
  2. Auditory Sensory Gating (P50)Time frame: 1 month corrected age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UC Health

    Aurora, Colorado · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.